Trial Profile
A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE TOLERABILITY AND PHARMACOKINETICS OF TWO SINGLE AND MULTIPLE HIGH DOSE REGIMENS OF BIA 2-093 IN HEALTHY VOLUNTEERS
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2015
Price :
$35
*
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Migraine; Neuropathic pain; Partial epilepsies; Postherpetic neuralgia
- Focus Adverse reactions
- Sponsors Bial
- 12 May 2015 New trial record